CheckMate 816 is the phase 3 clinical trial that established adding the immunotherapy drug nivolumab to standard chemotherapy before surgery as a new treatment approach for early-stage lung cancer. The trial enrolled 358 patients with resectable non-small cell lung cancer (NSCLC) and showed that the combination improved both the chances of the tumor being completely eliminated by the time of surgery and the length of time patients lived without their cancer returning or progressing.1PubMed Central. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer In 2022, the U.S. FDA approved this regimen based on the trial’s results, making it the first neoadjuvant chemoimmunotherapy approved for lung cancer. The trial’s influence stretches well beyond that approval, reshaping how oncologists and surgeons think about treating operable lung tumors.
What the Trial Tested and Who Was Enrolled
CheckMate 816 was an open-label, international, randomized trial that compared three cycles of nivolumab plus platinum-based chemotherapy against three cycles of platinum-based chemotherapy alone, both given before planned surgical removal of the tumor. Patients had stage IB (tumors at least 4 cm) through stage IIIA NSCLC, meaning their cancers were considered surgically removable but carried a meaningful risk of returning after surgery.2PubMed Central. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer The idea of giving treatment before surgery (neoadjuvant therapy) is not new in lung cancer. Chemotherapy alone before surgery had been used for years with modest benefits. What CheckMate 816 asked was whether adding an immune checkpoint inhibitor, nivolumab, to that pre-surgical chemotherapy could meaningfully improve outcomes.
Nivolumab works by blocking PD-1, a protein on the surface of immune cells that tumors exploit to avoid being attacked. By blocking PD-1 before the tumor is removed, the drug can help the immune system mount a stronger response while the bulk of the tumor is still present. Recent evidence suggests that giving immunotherapy before surgery, rather than after, can expand and modify tumor-targeting immune cells in ways that enhance both local and body-wide anti-tumor immunity.3PubMed Central. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy The intact tumor, in this model, serves as a kind of training ground for the immune system before it is surgically removed.
Pathological Response and What It Means
One of the trial’s two primary endpoints was pathological complete response (pCR), defined as zero percent residual viable tumor in both the primary tumor and surrounding lymph nodes at the time of surgery. This is the gold standard for measuring how thoroughly the neoadjuvant treatment killed the cancer before the surgeon even picked up a scalpel. CheckMate 816 showed a statistically significant improvement in pCR with the nivolumab combination compared to chemotherapy alone.4Journal of Clinical Oncology. Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816 The trial also tracked major pathological response (MPR), defined as 10% or less residual viable tumor, as a secondary endpoint.
The importance of pCR goes beyond being a snapshot at one point in time. Analyses from CheckMate 816 found that achieving a pathological response in the primary tumor was associated with improved event-free survival (EFS), meaning patients whose tumors showed deeper responses to pre-surgical treatment were less likely to have their cancer recur.5Journal of Clinical Oncology. Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816 This connection between what the pathologist sees under the microscope and what happens to the patient over the following years matters because it helps validate pCR as a meaningful early indicator of long-term benefit.
Event-Free Survival Over Time
The other primary endpoint, EFS, captures the time from randomization until cancer recurrence, progression that prevents surgery, or death from any cause. A four-year update of the trial, with a median follow-up of nearly 58 months, showed that median EFS was 43.8 months with nivolumab plus chemotherapy compared to 18.4 months with chemotherapy alone. The hazard ratio was 0.66, meaning the risk of an EFS event was about a third lower in the nivolumab group. Four-year EFS rates were 49% versus 38%.6Journal of Clinical Oncology. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816
These EFS numbers represent a substantial shift. For patients with operable but relatively advanced lung cancer, delaying recurrence by more than two years on average translates into a meaningfully different experience of life after surgery. It is worth noting that EFS, while clinically valuable, is not the same as overall survival. A patient whose cancer recurs later may still receive additional treatment. The question everyone ultimately cares about is whether patients actually live longer.
The Overall Survival Question
For years after the initial results were reported, the overall survival data from CheckMate 816 were immature, meaning not enough patients had died for the statistical analysis to reach a definitive conclusion. That changed with the final analysis, published in the New England Journal of Medicine, at a median follow-up of 68.4 months. The results significantly favored the nivolumab combination, with a hazard ratio for death of 0.72. Five-year overall survival was 65.4% with nivolumab plus chemotherapy compared to 55.0% with chemotherapy alone.7PubMed. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
That roughly ten-percentage-point difference at five years is clinically meaningful for a cancer that, historically, carried high recurrence rates even after successful surgery. The benefit was consistent across most subgroups examined. The earlier four-year interim analysis had already shown a sustained improvement of about 13 percentage points in overall survival (71% versus 58% at four years), though at that time the pre-specified statistical boundary for declaring formal significance had not been crossed.8Journal of Clinical Oncology. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816 The final analysis settled the question: neoadjuvant nivolumab plus chemotherapy helps patients with resectable lung cancer live longer.
Who Benefits Most and the Role of PD-L1
Not every patient benefits equally. Subgroup analyses from CheckMate 816, and a broader meta-analysis pooling data from multiple similar trials, have explored whether tumor PD-L1 expression levels predict how much a patient gains from adding immunotherapy. PD-L1 is the protein on tumor cells that interacts with PD-1 on immune cells; higher levels generally suggest the tumor is more reliant on this immune-evasion tactic, and so blocking it should be more effective.
The meta-analysis found that neoadjuvant immunotherapy plus chemotherapy improved pCR and EFS across all PD-L1 subgroups, including patients whose tumors had less than 1% PD-L1 expression. The EFS benefit was present whether PD-L1 was below 1%, between 1% and 49%, or at 50% and above, with the strongest effects in the highest-expressing group.9Journal of Clinical Oncology. The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis However, the overall survival story is more nuanced. In the pooled analysis, patients with PD-L1 of 1% or higher saw a significant survival benefit, while patients with PD-L1 below 1% did not show a statistically significant improvement in overall survival.10Journal of Clinical Oncology. The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis
Stage also matters. A review of CheckMate 816 noted that patients with stage IIIA disease appeared to derive greater benefit than those with stage IB or II.11European Respiratory Journal. The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer This makes intuitive sense: patients with more advanced resectable disease have the most to gain from a more aggressive systemic approach, while those with very early-stage tumors may already do well with surgery and conventional chemotherapy. In clinical practice, these biomarker and staging results help oncologists tailor treatment discussions, though the current approval does not restrict the regimen to any particular PD-L1 level.
Surgical Feasibility and Safety
A central worry about giving immunotherapy before surgery is that it could cause complications or delays that make the operation harder or even impossible. CheckMate 816 addressed this directly. Definitive surgery rates were 83% in the nivolumab plus chemotherapy arm compared to 75% with chemotherapy alone. The rate of complete (R0) resection was 83% versus 78%. Median residual viable tumor cells in the primary tumor bed were 10% with the combination versus 74% with chemotherapy alone, reflecting the deeper pathological responses already described. Surgery duration and length of hospital stay were comparable between the two arms, and surgical complication rates were not increased.12Journal of Clinical Oncology. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)
A Japanese subgroup analysis from the trial found even higher surgery rates, with about 94% of nivolumab-treated Japanese patients proceeding to surgery compared to roughly 83% in the chemotherapy-alone arm.13PubMed Central. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816 Separately, a study of surgical outcomes in patients who received neoadjuvant nivolumab (alone or with ipilimumab) found that postoperative complication rates were comparable to what one would expect from lung resection performed upfront or after chemotherapy alone, with all resected patients achieving complete (R0) margins.14PubMed Central. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer
When Immune Side Effects Complicate the Plan
Despite the overall reassuring safety picture, immunotherapy does carry a specific category of risk that chemotherapy alone does not: immune-related adverse events (irAEs). These are side effects caused by the immune system attacking the body’s own tissues, such as inflammation of the thyroid, liver, lungs, or skin. A multicenter retrospective analysis found that about 18.5% of patients receiving neoadjuvant nivolumab plus chemotherapy experienced preoperative irAEs. Patients who developed these side effects had a significantly lower rate of completing all three planned cycles of neoadjuvant therapy (about 58% completed, versus roughly 93% in those without irAEs). More concerning, surgery was cancelled in about 22% of patients with irAEs, compared to about 6% in those without.15JTO Clinical and Research Reports. Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis
This is an important caveat. While most patients tolerate the regimen well and proceed smoothly to surgery, a meaningful minority develops immune-related problems that can delay or derail the surgical plan. Clinicians managing these patients need to weigh the benefits of immunotherapy against the possibility that a side effect could interfere with the operation that remains the cornerstone of cure. In practice, close monitoring during the neoadjuvant period and early management of irAEs are essential parts of making this strategy work.
How Radiological Scans Compare to Pathological Findings
One practical challenge with neoadjuvant immunotherapy is that the scans done before surgery do not always tell the full story. Immunotherapy can cause inflammation and immune cell infiltration into the tumor, sometimes making it look the same size or even larger on imaging even though the cancer cells are being killed. A study examining pretreatment tumor growth rate and radiological response as predictors found only a moderate difference in EFS based on the tumor’s response as measured by standard imaging criteria (RECIST), and no significant difference in overall survival based on radiological response alone.16PubMed Central. Pretreatment Tumor Growth Rate and Radiological Response as Predictive Markers of Pathological Response and Survival in Patients with Resectable Lung Cancer Treated by Neoadjuvant Treatment
This disconnect between what a CT scan shows and what the pathologist ultimately finds in the removed tumor is something both patients and doctors should understand. A scan that looks mediocre after neoadjuvant chemoimmunotherapy does not necessarily mean the treatment failed. Conversely, some patients whose tumors shrink dramatically on scans may still have residual viable cancer. This is one reason why pCR, assessed only after the tumor is out, has become such a valued endpoint in neoadjuvant immunotherapy trials.
Real-World Experience Beyond the Trial
Clinical trials select patients carefully and treat them in controlled settings, so an important question is whether CheckMate 816’s results hold up in everyday practice. Early real-world data have been encouraging. A retrospective analysis of patients with stage IB to IIIA NSCLC who received neoadjuvant nivolumab plus chemotherapy outside of a trial found that about 54% achieved a major or complete pathological response, and all patients in that cohort were able to undergo surgical resection by lobectomy.17Journal of Thoracic Oncology. Real-World Outcomes of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Non-Small Cell Lung Cancer A separate multicenter real-world safety study also concluded that the feasibility of neoadjuvant chemoimmunotherapy in clinical practice was consistent with what the randomized trials had shown.18The Annals of Thoracic Surgery. Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus)
These real-world datasets are still small, and longer follow-up is needed to confirm that the survival benefits track with trial results. But the early signal suggests that the approach translates reasonably well from the carefully managed environment of a clinical trial to the messier reality of routine cancer care.
Cost-Effectiveness and Access
Immunotherapy drugs are expensive, and adding nivolumab to chemotherapy before surgery raises the total cost of treatment. The question of whether the clinical benefit justifies the price has been examined from several angles. One U.S.-based cost-effectiveness analysis found that perioperative nivolumab combined with neoadjuvant chemotherapy had an incremental cost-effectiveness ratio (ICER) of roughly $101,000 per quality-adjusted life year (QALY) gained compared to chemotherapy alone, which falls under the commonly cited $150,000-per-QALY willingness-to-pay threshold in the United States.19PubMed. Cost-Effectiveness of Perioperative Nivolumab for Stage III Non-Small-Cell Lung Cancer: A Perspective From The United States
Interestingly, a European analysis framed the economics differently. Looking at neoadjuvant nivolumab plus chemotherapy (without extended adjuvant immunotherapy afterward), the analysis found that the combination resulted in a QALY gain of about 1.37 years and was actually cost-saving compared to chemotherapy alone, yielding savings of roughly €4,200.20Value in Health. Cost-Effectiveness and Financial Toxicity of Adding Neoadjuvant Nivolumab to Standard Chemotherapy in Resectable Non-Small Cell Lung Cancer The difference between these analyses comes down to what treatment strategy is being modeled (neoadjuvant only versus perioperative, which adds post-surgical immunotherapy), what comparators are used, and the healthcare system’s pricing structure. The broader point is that, depending on the specific approach, the addition of nivolumab appears either cost-effective or cost-saving, though healthcare systems with different cost structures and willingness-to-pay thresholds will reach different conclusions.
A separate U.S. analysis compared perioperative nivolumab to several alternative strategies and found varied ICERs depending on the comparator, ranging from about $22,000 per QALY versus perioperative durvalumab plus chemotherapy up to roughly $154,000 per QALY versus neoadjuvant nivolumab plus chemotherapy alone (meaning the neoadjuvant-only strategy, without the adjuvant extension).21PubMed. Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States This comparison highlights an emerging debate about whether patients need immunotherapy only before surgery, or both before and after.
Neoadjuvant Versus Perioperative Strategies
CheckMate 816 tested nivolumab only in the neoadjuvant (pre-surgery) setting. But several newer trials, including CheckMate 77T, KEYNOTE-671, and AEGEAN, have tested “perioperative” strategies, where immunotherapy is given both before and after surgery, sometimes for up to a year post-operatively. This raises a practical question for patients and oncologists: is the pre-surgery treatment enough, or do you need to continue immunotherapy afterward?
The honest answer is that the field has not definitively resolved this. No head-to-head trial has directly compared a neoadjuvant-only approach against a full perioperative strategy. Cross-trial comparisons are inherently unreliable because the patient populations, staging systems, and follow-up durations differ. Some researchers have attempted patient-level analyses comparing CheckMate 77T and CheckMate 816 data, but these remain exploratory. In clinical practice, many oncologists are now using perioperative strategies for patients with higher-risk disease while considering neoadjuvant-only approaches for patients who achieve a complete pathological response at surgery. The optimal duration and timing of immunotherapy around surgery is one of the most actively debated questions in thoracic oncology today.
Remaining Uncertainties and Open Questions
Despite the clear advances CheckMate 816 represents, several questions remain. The trial used the older 7th edition of the AJCC staging system, which defines stages differently than the current 8th edition. This means that some patients classified as stage IIIA in the trial might be reclassified under newer staging. It is a nuance, but one that affects how clinicians apply the data to patients staged using current criteria.
Another unresolved issue is what to do for patients with specific genomic alterations, particularly EGFR mutations or ALK rearrangements. These patients typically respond to targeted therapies rather than immunotherapy, and they were underrepresented in CheckMate 816. Most oncologists would not use neoadjuvant immunotherapy for patients whose tumors carry these actionable mutations, but the evidence base specifically addressing this group in the neoadjuvant setting remains thin.
Finally, the relationship between circulating tumor DNA (ctDNA) clearance after neoadjuvant treatment and long-term outcomes is an area of active research. If a blood test could reliably identify which patients have already been cured by neoadjuvant therapy, it might spare some from unnecessary additional treatment while flagging others who need more aggressive follow-up. CheckMate 816 has contributed some data to this effort, but ctDNA-guided treatment decisions are not yet part of standard care.